MEK blockade overcomes the limited activity of palbociclib in head and neck cancer

Head and neck cancer (HNC) is characterized with multiple aberrations in cell cycle pathways, including amplification of cyclin D1. Palbociclib (PAL), a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has been reported to regulate cell cycle progression in HNC. However, recent studies have revealed...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Zhenghuan, Jung, Kyung Hee, Lee, Ji Eun, Cho, Jinhyun, Lim, Joo Han, Hong, Soon-Sun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385517/
https://www.ncbi.nlm.nih.gov/pubmed/32712554
http://dx.doi.org/10.1016/j.tranon.2020.100833

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385517/
https://www.ncbi.nlm.nih.gov/pubmed/32712554
http://dx.doi.org/10.1016/j.tranon.2020.100833

Ejemplares similares